Eurizon Capital SGR S.p.A. Takes $82.35 Million Position in Bristol Myers Squibb Company $BMY

Eurizon Capital SGR S.p.A. acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 1,526,318 shares of the biopharmaceutical company’s stock, valued at approximately $82,354,000.

Several other large investors have also modified their holdings of BMY. Geode Capital Management LLC boosted its holdings in shares of Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares during the period. Man Group plc boosted its holdings in shares of Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after acquiring an additional 5,503,391 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Bristol Myers Squibb by 530.6% during the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock worth $245,946,000 after purchasing an additional 4,588,601 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Bristol Myers Squibb by 67.8% during the third quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock worth $444,682,000 after purchasing an additional 3,982,439 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Bristol Myers Squibb by 31.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock worth $669,012,000 after purchasing an additional 3,522,696 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on BMY shares. Barclays started coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target for the company. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. Wells Fargo & Company reaffirmed an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMS reported encouraging late-stage data for mezigdomide, saying the experimental CELMoD cut the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma. That is the kind of readout investors watch for because it strengthens the case for a future commercial opportunity. Article Title
• Positive Sentiment: The company also highlighted mezigdomide data in a business update, reinforcing optimism around its broader oncology pipeline and suggesting Celgene-derived assets continue to support long-term growth prospects. Article Title
• Positive Sentiment: Bristol Myers Squibb said it is backing a new cell-therapy combination in an early gastrointestinal cancer trial, which adds another potential pipeline catalyst and underscores continued investment in high-value cancer programs. Article Title
• Positive Sentiment: BMS also announced a strategic partnership with Anthropic to use Claude across research, clinical development, manufacturing, commercial, and corporate functions, a move that could improve productivity and speed decision-making over time. Article Title

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Trading Up 0.5%

Shares of BMY stock opened at $57.17 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock has a market cap of $116.75 billion, a P/E ratio of 16.06, a P/E/G ratio of 0.16 and a beta of 0.26. The business has a fifty day simple moving average of $58.32 and a 200-day simple moving average of $56.26. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter last year, the business posted $1.80 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.